Antibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- HPA002037 - Provider product page
- Provider
- Atlas Antibodies
- Proper citation
- Atlas Antibodies Cat#HPA002037, RRID:AB_1851483
- Product name
- Anti-IGF2BP3
- Antibody type
- Polyclonal
- Description
- Polyclonal Antibody against Human IGF2BP3, Gene description: insulin-like growth factor 2 mRNA binding protein 3, Alternative Gene Names: CT98, IMP-3, IMP3, Validated applications: WB, IHC, Uniprot ID: O00425, Storage: Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 100 µl
- Concentration
- 0.2 mg/ml
- Storage
- Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Handling
- The antibody solution should be gently mixed before use.
Submitted references Multi-Omic Analysis of Esophageal Adenocarcinoma Uncovers Candidate Therapeutic Targets and Cancer-Selective Posttranscriptional Regulation
IGF2BP3 promotes the progression of colorectal cancer and mediates cetuximab resistance by stabilizing EGFR mRNA in an m6A-dependent manner
Comprehensive analysis of the prognostic impact and immune implication of KIAA1429 in lung adenocarcinoma
IGF2 mRNA binding protein 3 (IMP3) promotes glioma cell migration by enhancing the translation of RELA/p65
O'Neill J, Yébenes Mayordomo M, Mitulović G, Al Shboul S, Bedran G, Faktor J, Hernychova L, Uhrik L, Gómez-Herranz M, Kocikowski M, Save V, Vojtěšek B, Arends M, Fitzgerald R, Edwards P, Grehan N, Nutzinger B, Loreno C, Redmond A, Abbas S, Freeman A, Smyth E, O'Donovan M, Miremadi A, Malhotra S, Tripathi M, Cheah C, Coles H, Millington C, Devonshire G, Eldridge M, Secrier M, Jammula S, Davies J, Crichton C, Carroll N, Hardwick R, Safranek P, Hindmarsh A, Sujendran V, Hayes S, Ang Y, Sharrocks A, Preston S, Bagwan I, Save V, Skipworth R, Hupp T, O'Neill J, Tucker O, Beggs A, Taniere P, Puig S, Contino G, Underwood T, Walker R, Grace B, Lagergren J, Gossage J, Davies A, Chang F, Mahadeva U, Goh V, Ciccarelli F, Sanders G, Berrisford R, Chan D, Cheong E, Kumar B, Sreedharan L, Parsons S, Soomro I, Kaye P, Saunders J, Lovat L, Haidry R, Scott M, Sothi S, Lishman S, Hanna G, Peters C, Moorthy K, Grabowska A, Turkington R, McManus D, Coleman H, Petty R, Bartlet F, Hupp T, Alfaro J
Molecular & Cellular Proteomics 2024;23(6):100764
Molecular & Cellular Proteomics 2024;23(6):100764
IGF2BP3 promotes the progression of colorectal cancer and mediates cetuximab resistance by stabilizing EGFR mRNA in an m6A-dependent manner
Chen L, Liu H, Xiao Z, Qiu T, Zhang D, Zhang L, Han F, Chen G, Xu X, Zhu J, Ding Y, Wang S, Ye Y, Jiao H
Cell Death & Disease 2023;14(9)
Cell Death & Disease 2023;14(9)
Comprehensive analysis of the prognostic impact and immune implication of KIAA1429 in lung adenocarcinoma
Guo L, Huai Q, Zhou B, Ying J, Guo W
Cancer Innovation 2022;1(4):328-343
Cancer Innovation 2022;1(4):328-343
IGF2 mRNA binding protein 3 (IMP3) promotes glioma cell migration by enhancing the translation of RELA/p65
Bhargava S, Visvanathan A, Patil V, Kumar A, Kesari S, Das S, Hegde A, Arivazhagan A, Santosh V, Somasundaram K
Oncotarget 2017;8(25):40469-40485
Oncotarget 2017;8(25):40469-40485
No comments: Submit comment
No validations: Submit validation data